Page 86 - Read Online

Sharma et al. Cancer Drug Resist 2023;6:688-708 https://dx.doi.org/10.20517/cdr.2023.82 Page 702

Rep 2021;21:67. DOI PubMed
7. Grochans S, Cybulska AM, Simińska D, et al. Epidemiology of glioblastoma multiforme-literature review. Cancers 2022;14:2412.
DOI PubMed PMC
8. Fisher JP, Adamson DC. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines 2021;9:324. DOI
PubMed PMC
9. Xue J, Wu Y, Liu N. Ultrasound enhanced anti-tumor effect of temozolomide in glioblastoma cells and glioblastoma mouse model.
Cell Mol Bioeng 2019;12:99-106. DOI PubMed PMC
10. Barker CA, Chang M, Chou JF, et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with
glioblastoma. J Neurooncol 2012;109:391-7. DOI PubMed PMC
11. Noch EK, Ramakrishna R, Magge R. Challenges in the treatment of glioblastoma: multisystem mechanisms of therapeutic resistance.
World Neurosurg 2018;116:505-17. DOI PubMed
12. Nicholas MK. Glioblastoma multiforme: evidence-based approach to therapy. Expert Rev Anticancer Ther 2007;7:S23-7. DOI
PubMed
13. Whelan R, Hargaden GC, Knox AJS. Modulating the blood-brain barrier: a comprehensive review. Pharmaceutics 2021;13:1980.
DOI PubMed PMC
14. Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity.
Fluids Barriers CNS 2020;17:69. DOI PubMed PMC
15. Hladky SB, Barrand MA. Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-
brain barrier. Fluids Barriers CNS 2018;15:30. DOI PubMed PMC
16. Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and dysfunction of the blood-brain barrier. Cell 2015;163:1064-78.
DOI PubMed PMC
17. Simon MJ, Iliff JJ. Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease.
Biochim Biophys Acta 2016;1862:442-51. DOI PubMed PMC
18. Wolburg H, Wolburg-Buchholz K, Liebner S, Engelhardt B. Claudin-1, claudin-2 and claudin-11 are present in tight junctions of
choroid plexus epithelium of the mouse. Neurosci Lett 2001;307:77-80. DOI PubMed
19. Bhalerao A, Sivandzade F, Archie SR, Chowdhury EA, Noorani B, Cucullo L. In vitro modeling of the neurovascular unit: advances
in the field. Fluids Barriers CNS 2020;17:22. DOI PubMed PMC
20. Kane JR. The role of brain vasculature in glioblastoma. Mol Neurobiol 2019;56:6645-53. DOI PubMed
21. de Gooijer MC, Kemper EM, Buil LCM, et al. ATP-binding cassette transporters restrict drug delivery and efficacy against brain
tumors even when blood-brain barrier integrity is lost. Cell Rep Med 2021;2:100184. DOI PubMed PMC
22. Qosa H, Miller DS, Pasinelli P, Trotti D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological
disorders. Brain Res 2015;1628:298-316. DOI PubMed PMC
23. Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005;2:86-98.
DOI PubMed PMC
24. Liu H, Yu N, Lu S, et al. Solute carrier family of the organic anion-transporting polypeptides 1A2- Madin-Darby Canine Kidney II: a
promising in vitro system to understand the role of organic anion-transporting polypeptide 1A2 in blood-brain barrier drug
penetration. Drug Metab Dispos 2015;43:1008-18. DOI
25. He L, Vasiliou K, Nebert DW. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics 2009;3:195-
206. DOI PubMed PMC
26. Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica
2008;38:778-801. DOI PubMed
27. Thakkar N, Lockhart AC, Lee W. Role of organic anion-transporting polypeptides (OATPs) in cancer therapy. AAPS J 2015;17:535-
45. DOI PubMed PMC
28. Bronger H, König J, Kopplow K, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the
blood-tumor barrier. Cancer Res 2005;65:11419-28. DOI
29. Cooper E, Woolf Z, Swanson MEV, et al. Single-cell image analysis reveals over-expression of organic anion transporting
polypeptides (OATPs) in human glioblastoma tissue. Neurooncol Adv 2022;4:vdac166. DOI PubMed PMC
30. Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 2012;5:102-
14. DOI PubMed
31. Wu S, Li X, Gao F, de Groot JF, Koul D, Yung WKA. PARP-mediated PARylation of MGMT is critical to promote repair of
temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol 2021;23:920-31. DOI PubMed PMC
32. Lin K, Gueble SE, Sundaram RK, Huseman ED, Bindra RS, Herzon SB. Mechanism-based design of agents that selectively target
drug-resistant glioma. Science 2022;377:502-11. DOI PubMed PMC
33. Tirrò E, Massimino M, Romano C, et al. Prognostic and therapeutic roles of the insulin growth factor system in glioblastoma. Front
Oncol 2020;10:612385. DOI PubMed PMC
34. Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis 2016;3:198-210. DOI PubMed PMC
35. Jimenez-Pascual A, Siebzehnrubl FA. Fibroblast growth factor receptor functions in glioblastoma. Cells 2019;8:715. DOI PubMed
PMC
36. Li X, Wu C, Chen N, et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 2016;7:33440-50.